BioCentury | Sep 16, 2013
Clinical News

TCN-202: Phase IIa started

...in up to 20 renal transplant recipients to evaluate TCN-202 for 10 weeks following transplantation. TCN-202...
...to close next quarter (see BioCentury, Aug. 5). Theraclone Sciences Inc. , Seattle, Wash. Product: TCN-202...
BioCentury | Aug 5, 2013
Company News

PharmAthene, Theraclone deal

...was financial advisor to Theraclone. The combined company's pipeline will include two Theraclone antibody products, TCN-202...
...I-STAR technology, which can screen human memory B cells to identify antibodies against relevant targets. TCN-202...
BioCentury | Apr 8, 2013
Clinical News

TCN-202: Phase I data

...a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 40 healthy volunteers showed that IV TCN-202...
...or serious adverse events reported. No antibodies against TCN-202 were detected. Theraclone also said that TCN-202...
...received placebo or single ascending-doses of 1-50 mg/kg TCN-202 or 2 doses of 15 mg/kg TCN-202...
BioCentury | Jun 18, 2012
Clinical News

TCN-202: Phase I started

...to evaluate single and multiple doses of IV TCN-202 in up to 80 healthy volunteers. TCN-202...
...Orphan Drug designation to treat congenital CMV infection. Theraclone Sciences Inc. , Seattle, Wash. Product: TCN-202...
Items per page:
1 - 4 of 4